COVID-19 Gives Gilead A Down Quarter, But Guidance Boosted By Remdesivir
Executive Summary
Sales were down in the second quarter to $5.07bn, primarily due to coronavirus-related impacts, but Gilead’s COVID-19 antiviral therapy remdesivir will boost revenues in the second half.
You may also be interested in...
Coronavirus Update: Roche's Actemra Fails In Phase III COVID Study
Disappointment as Roche/Chugai antibody tocilizumab misses most endpoints.
EMA Says Yes To GSK’s Belantamab But Rejects Tagraxofusp & Emapalumab
GlaxoSmithKline's first-of-its kind treatment for multiple myeloma is among 11 new medicines that have won an EU approval nod from the European Medicines Agency this week.
Gilead Sets Remdesivir Price, Commits Nearly All Near-Term Supplies To US
A five-day course will cost $2,340 for governments in developed countries and $3,120 for commercial payers. The US will get 100% of remdesivir manufactured by Gilead in July.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports